Health DiagnosticsImmunologyPharmacovigilanceGeneticsBiotechnology
Description
Analysis
Middle-of-the-road
Samsung Biologics Co.,Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 35.0×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 14% a year, against analyst forecasts of 55%. The price, in other words, assumes less than the experts do.
Growth is solid; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202351
43
2023202420252026
All-time high
65
Jan 2025
All-time low
25
Jan 2024
Average rank
43
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
5
3
3
1
Price/Earnings
21
3
10
7
Price/Book
20
10
7
5
Dividend Yield
1
1
1
1
Value (overall)
1
4
8
5
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.